{"id":"free-doxorubicin-hydrochloride","safety":{"commonSideEffects":[{"rate":"60-80%","effect":"Myelosuppression"},{"rate":"5-20%","effect":"Cardiotoxicity"},{"rate":"70-90%","effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Doxorubicin hydrochloride functions by inserting itself between the base pairs of the DNA double helix (intercalation), which prevents DNA replication and transcription. Additionally, it inhibits topoisomerase II, an enzyme that helps manage the topology of DNA, causing double-strand breaks and further disrupting DNA function, ultimately leading to apoptosis.","oneSentence":"Doxorubicin hydrochloride intercalates DNA and inhibits topoisomerase II, leading to DNA damage and cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:55.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Lung cancer"},{"name":"Leukemia"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT07463313","phase":"PHASE2, PHASE3","title":"6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":"Thymoma and Thymic Carcinoma","enrollment":116},{"nctId":"NCT07102940","phase":"PHASE2","title":"Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2026-05-01","conditions":"Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":50},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":29},{"nctId":"NCT04028063","phase":"PHASE2","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-01-28","conditions":"Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma","enrollment":65},{"nctId":"NCT07320508","phase":"PHASE2","title":"Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2026-01-20","conditions":"Adenoid Cystic Carcinoma, Sinonasal Carcinoma, Epirubicin","enrollment":100},{"nctId":"NCT05114720","phase":"PHASE3","title":"Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-11-11","conditions":"Breast Cancer","enrollment":559},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT02066220","phase":"PHASE2, PHASE3","title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2014-06","conditions":"Brain Tumors","enrollment":360},{"nctId":"NCT05929768","phase":"PHASE3","title":"Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-09-15","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":2400},{"nctId":"NCT03283384","phase":"PHASE2","title":"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2019-06-15","conditions":"Breast Neoplasms","enrollment":100},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT04762069","phase":"PHASE2","title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"CNS Pharmaceuticals, Inc.","startDate":"2021-05-18","conditions":"Glioblastoma Multiforme, Adult","enrollment":210},{"nctId":"NCT06954805","phase":"PHASE2","title":"Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)","status":"RECRUITING","sponsor":"Jennifer Amengual","startDate":"2025-04-14","conditions":"Lymphoma, Lymphoma, B-Cell","enrollment":30},{"nctId":"NCT02891824","phase":"PHASE3","title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2016-09-22","conditions":"Ovarian Cancer","enrollment":614},{"nctId":"NCT06753721","phase":"PHASE1, PHASE2","title":"An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-12-31","conditions":"Advanced Colorectal Adenocarcinoma","enrollment":13},{"nctId":"NCT06674096","phase":"PHASE2","title":"RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-11-06","conditions":"Double-expressor Lymphoma","enrollment":44},{"nctId":"NCT05257018","phase":"PHASE2","title":"R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-02-26","conditions":"Diffuse Large B-cell Lymphoma","enrollment":83},{"nctId":"NCT03712202","phase":"PHASE2","title":"Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-11-28","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma","enrollment":155},{"nctId":"NCT03598270","phase":"PHASE3","title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-11-21","conditions":"Recurrent Ovarian Carcinoma","enrollment":417},{"nctId":"NCT00991211","phase":"PHASE3","title":"Bendamustine Plus Rituximab Versus CHOP Plus Rituximab","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2004-01","conditions":"Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas","enrollment":549},{"nctId":"NCT05207514","phase":"PHASE3","title":"Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer","status":"TERMINATED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2022-03-31","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT03817853","phase":"PHASE4","title":"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-26","conditions":"Advanced Follicular Lymphoma","enrollment":114},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT00712881","phase":"PHASE2","title":"Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Cephalon, Inc.","startDate":"2008-10-13","conditions":"Breast Cancer","enrollment":126},{"nctId":"NCT03907969","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-10-09","conditions":"Advanced Malignancies","enrollment":30},{"nctId":"NCT00657878","phase":"PHASE3","title":"Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2008-11","conditions":"Ovarian Cancer","enrollment":215},{"nctId":"NCT06092606","phase":"PHASE2","title":"A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients","status":"UNKNOWN","sponsor":"Monyan Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2023-04-04","conditions":"Cancer, Heart Failure, Arrhythmia","enrollment":90},{"nctId":"NCT05290090","phase":"PHASE2","title":"ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":31},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT00006734","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2001-05","conditions":"Sarcoma","enrollment":587},{"nctId":"NCT05874778","phase":"PHASE2","title":"A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-15","conditions":"Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy","enrollment":108},{"nctId":"NCT00121992","phase":"PHASE3","title":"Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"1999-07","conditions":"Breast Neoplasms","enrollment":1060},{"nctId":"NCT00346125","phase":"NA","title":"PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-04-10","conditions":"Sarcoma","enrollment":70},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT05518383","phase":"PHASE4","title":"B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-05-25","conditions":"Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma","enrollment":300},{"nctId":"NCT00976911","phase":"PHASE3","title":"AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-29","conditions":"Ovarian Cancer","enrollment":361},{"nctId":"NCT04223583","phase":"PHASE4","title":"Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2019-06-26","conditions":"Soft Tissue Sarcomas","enrollment":70},{"nctId":"NCT04490993","phase":"PHASE3","title":"Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients","status":"UNKNOWN","sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","startDate":"2017-03-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":359},{"nctId":"NCT04887961","phase":"PHASE2","title":"Reprab Study: PLD + Trabectedin Rechallenge","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-10-01","conditions":"Relapsed Ovarian Cancer","enrollment":64},{"nctId":"NCT01837251","phase":"PHASE3","title":"Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"AGO Research GmbH","startDate":"2013-05","conditions":"Recurrent Platinum-sensitive Ovarian Cancer","enrollment":682},{"nctId":"NCT04899713","phase":"","title":"NEOZOL_Follow-up Study","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2021-05","conditions":"Locally Advanced Breast Cancer","enrollment":50},{"nctId":"NCT04699214","phase":"PHASE2","title":"Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment","status":"UNKNOWN","sponsor":"Yong Chen","startDate":"2020-09-01","conditions":"Other Disorders of Soft Tissues","enrollment":210},{"nctId":"NCT03023878","phase":"PHASE2","title":"Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-13","conditions":"High-risk Diffuse Large B-Cell Lymphoma","enrollment":47},{"nctId":"NCT01049425","phase":"PHASE3","title":"Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2009-02-05","conditions":"Primary Breast Cancer, Her2 Non-overexpressing","enrollment":3198},{"nctId":"NCT01918124","phase":"PHASE2","title":"A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer","status":"COMPLETED","sponsor":"Fan Ming","startDate":"2008-01","conditions":"Prosthesis Survival","enrollment":80},{"nctId":"NCT01281254","phase":"PHASE3","title":"AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)","status":"TERMINATED","sponsor":"Amgen","startDate":"2011-04-18","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer","enrollment":223},{"nctId":"NCT01313884","phase":"PHASE2","title":"Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma","status":"TERMINATED","sponsor":"Stanford University","startDate":"2011-05","conditions":"Bone Cancer, Ewing's Sarcoma","enrollment":3},{"nctId":"NCT00780039","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-10-01","conditions":"Ovarian Neoplasms","enrollment":58},{"nctId":"NCT03000036","phase":"NA","title":"Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2012-07","conditions":"Breast Cancer Female, Doxorubicin Induced Cardiomyopathy","enrollment":27},{"nctId":"NCT00931229","phase":"NA","title":"Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients","status":"UNKNOWN","sponsor":"National Health Research Institutes, Taiwan","startDate":"2009-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":202},{"nctId":"NCT00005945","phase":"PHASE3","title":"Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-06","conditions":"Leukemia","enrollment":3054},{"nctId":"NCT01697072","phase":"PHASE3","title":"First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-10","conditions":"Gastric Cancer","enrollment":609},{"nctId":"NCT02428751","phase":"PHASE3","title":"R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma","status":"UNKNOWN","sponsor":"Wenqi Jiang","startDate":"2015-09","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":216},{"nctId":"NCT02053597","phase":"PHASE2","title":"TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-10","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00494780","phase":"PHASE2","title":"Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Lymphoma, Follicular","enrollment":59},{"nctId":"NCT00719550","phase":"PHASE1, PHASE2","title":"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-02","conditions":"Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer","enrollment":130},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10},{"nctId":"NCT00790244","phase":"PHASE2","title":"A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-10","conditions":"Soft Tissue Sarcoma, Non Metastatic Disease","enrollment":188},{"nctId":"NCT00886028","phase":"PHASE2","title":"Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma","status":"UNKNOWN","sponsor":"National Institute of Cancerología","startDate":"2006-09","conditions":"Malignant Pleural Mesothelioma","enrollment":31},{"nctId":"NCT00309920","phase":"NA","title":"Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer","status":"UNKNOWN","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2004-01","conditions":"Breast Cancer","enrollment":1234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anthracycline"],"phase":"phase_2","status":"active","brandName":"Free doxorubicin hydrochloride","genericName":"Free doxorubicin hydrochloride","companyName":"Cephalon, Inc.","companyId":"cephalon-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxorubicin hydrochloride intercalates DNA and inhibits topoisomerase II, leading to DNA damage and cell death. Used for Breast cancer, Ovarian cancer, Lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}